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ORIGINAL ARTICLE
Evidence for genetic heterogeneity between clinical subtypes of
bipolar disorder
AW Charney1, DM Ruderfer1,2, EA Stahl1,2, JL Moran3, K Chambert3, RA Belliveau3, L Forty4, K Gordon-Smith5, A Di Florio4,6, PH Lee3,7,8,
EJ Bromet9, PF Buckley10, MA Escamilla11, AH Fanous12,13, LJ Fochtmann9, DS Lehrer14, D Malaspina15, SR Marder16, CP Morley17,18,19,
H Nicolini20,21, DO Perkins6, JJ Rakofsky22, MH Rapaport22, H Medeiros23, JL Sobell23, EK Green24, L Backlund25,26, SE Bergen3,27,
A Juréus27, M Schalling26, P Lichtenstein27, P Roussos1,2,28, JA Knowles23,29, I Jones4, LA Jones5, CM Hultman1,27, RH Perlis30,
SM Purcell1,2,28, SA McCarroll3,31, CN Pato23,29, MT Pato23,29, N Craddock4, M Landén27,32, JW Smoller3,7,8,33 and P Sklar1,2,28
We performed a genome-wide association study of 6447 bipolar disorder (BD) cases and 12 639 controls from the International
Cohort Collection for Bipolar Disorder (ICCBD). Meta-analysis was performed with prior results from the Psychiatric Genomics
Consortium Bipolar Disorder Working Group for a combined sample of 13 902 cases and 19 279 controls. We identified eight
genome-wide significant, associated regions, including a novel associated region on chromosome 10 (rs10884920; P= 3.28 × 10− 8)
that includes the brain-enriched cytoskeleton protein adducin 3 (ADD3), a non-coding RNA, and a neuropeptide-specific
aminopeptidase P (XPNPEP1). Our large sample size allowed us to test the heritability and genetic correlation of BD subtypes and
investigate their genetic overlap with schizophrenia and major depressive disorder. We found a significant difference in heritability
of the two most common forms of BD (BD I SNP-h2 = 0.35; BD II SNP-h2 = 0.25; P= 0.02). The genetic correlation between BD I and
BD II was 0.78, whereas the genetic correlation was 0.97 when BD cohorts containing both types were compared. In addition, we
demonstrated a significantly greater load of polygenic risk alleles for schizophrenia and BD in patients with BD I compared with
patients with BD II, and a greater load of schizophrenia risk alleles in patients with the bipolar type of schizoaffective disorder
compared with patients with either BD I or BD II. These results point to a partial difference in the genetic architecture of BD
subtypes as currently defined.
Translational Psychiatry (2017) 7, e993; doi:10.1038/tp.2016.242; published online 10 January 2017
INTRODUCTION
Bipolar disorder (BD) is a mental illness characterized by episodes
of mania and depression. Over the past century, the diagnostic
criteria for this condition have evolved. First, ‘manic-depressive
insanity’ was split from the condition that is today known as
schizophrenia (SCZ).1 It was then split from what we now
label major depressive disorder (MDD), and renamed BD.2
Subsequently, BD was formally divided into two clinical subtypes:
bipolar I disorder (BD I), characterized by manic episodes; and
bipolar II disorder (BD II), characterized by hypomanic episodes
and recurrent depressive episodes.3 The initial BD I and BD II
distinction was based primarily on a different longitudinal course,
as differences in family loading3 and lithium responsiveness4 were
not observed. The exact prevalence of each clinical subtype
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remains uncertain, with the most recent large epidemiological
study reporting lifetime prevalence of 0.6% for BD I and 0.4% for
BD II,5 similar to a recent systematic review6 but lower than
previously reported.7,8
Recurrence risk ratios for BD of 7–10 for first-degree relatives are
observed, and several family studies have aimed to evaluate
whether there is shared etiology for BD I and BD II. Some studies
have shown familial co-aggregation of BD and MDD,9 but
investigation of the specificity of familial aggregation of BD
subtypes and their relationship to MDD to determine whether BD
subtypes share etiology have yielded inconclusive results.10,11
More recently, contemporary family studies have found familial
aggregation of mania and major depressive episodes but not
hypomania,12 and, similarly, of BD I and MDD but not BD II.13
In addition to BD I, a manic episode is required for the DSM-V
diagnosis of schizoaffective disorder bipolar type (SAB). Since its
initial description in 193314 there has been debate regarding
whether schizoaffective disorder (SA) is a form of SCZ, affective
disorder, a combination of the two, or a separate entity altogether.
BD and SCZ have historically been regarded as genetically
distinct;12,15 however, more recent studies have shown a
significant shared genetic component of these disorders. A large
population-based study of 435 000 patients with SCZ, 40 000
patients with BD and their family members found an increased risk
of BD in first-degree relatives of SCZ probands, and vice versa.16,17
Compared with SCZ and BD, there is evidence that SA shows
weaker disorder-specific familial aggregation, with relatives of SA
probands having relatively equivalent risk for SA, SCZ and BD.15,18
Genetic studies of common variation in BD have identified
multiple genome-wide significant associations between disease
status and single nucleotide polymorphisms (SNPs).19–27 In 2011,
the Psychiatric Genomics Consortium Bipolar Disorder Working
Group (PGCBD) reported four loci meeting genome-wide sig-
nificance, including regions in close proximity to genes ODZ4,
ANK3 and SYNE1.24 Subsequently two studies performed meta-
analyses incorporating the PGCBD data and their own new
samples: Chen et al.26 identified novel associations near the genes
TRANK1 (LBA1), LMAN2L and PTGFR; Muhleisen et al.27 identified
two new risk loci near ADCY2 and a region between MIR2113 and
POU3F2. As demonstrated in other disorders, in particular SCZ,28
increasing sample size led to the identification of additional
associated loci. Although each genome-wide association study
(GWAS) only found a handful of genome-wide significant
associations, it has been convincingly demonstrated that BD is
polygenic; there are many common DNA variants whose effects
are too small to detect individually, but when summed together,
are contributing to BD risk.
Traditional family studies focus on relatives to determine the
proportion of variance of liability to disease that is attributable to
inherited genetic factors. In the absence of molecular data, these
studies provide no information about the number, frequency or
effect sizes of any genes or associated variants involved. With the
emergence of genome-wide data for multiple psychiatric dis-
orders, several methods have been developed for comparing
conditions to one another at the genetic level. Three commonly
used analytic approaches are comparative GWAS, polygenic
scoring29 and SNP-based heritability estimation.30–32 Cross-
disorder analysis of individual SNPs in SCZ and mood disorders
(BD I, BD II, MDD) reported a genome-wide significant locus on
chromosome 11 that appeared to be specific to BD II.33 Because
there are many small-effect DNA variants, polygenic scoring
methods were developed that derive a disease risk score for each
individual in a data set by counting the number of previously
identified risk alleles present. Polygenic scores derived from both
SCZ- and MDD-risk alleles have discriminant ability between BD
cases and controls.17,34 SNP-based heritability methods, as
opposed to utilizing genetic data only from loci previously
implicated in disease, make genetic relatedness calculations by
comparing all possible pairs of individuals in a data set at all
genetic markers. When this information has been determined for
two independent case–control data sets, the proportion of
variance in phenotype explained by SNPs (labeled the SNP-
based heritability, or SNP-h2) for each case trait and the genetic
correlation (rg)
[ref. 35] between the case traits can be determined.
Using this approach, SNP-h2 has been estimated to range between
0.20 and 0.25 for BD, SCZ and MDD, whereas the BD-MDD and BD-
SCZ genetic correlations have been estimated at 50% and 70%,
respectively.30 The effect of BD subtype composition on these
estimates has not been investigated.
In order to markedly increase the available sample size for a
GWAS and improve our power to identify risk loci and discern
genetic differences across BD subtypes, we established the
International Cohort Collection for Bipolar Disorder (ICCBD) with
investigators from the United States (US), United Kingdom (UK)
and Sweden. We performed a GWAS on the ICCBD sample, as well
as a meta-analysis with the PGCBD for a total of 13 902 cases and
19 279 controls. Further, we took advantage of the size and
composition of our sample to explicitly survey the genetic
relationship across the clinical subtypes of BD (BD I, BD II and
SAB). Specifically, we compare SNP-based measures of heritability
and genetic correlation for BD I and BD II, and assess the polygenic
loading of BD subtypes for risk alleles identified previously
through large-scale GWAS of three psychiatric disorders (BD,
SCZ and MDD).
MATERIALS AND METHODS
Subject ascertainment and sample collection
All procedures were approved by ethical committees at the Karolinska
Institutet, University of Southern California and Cardiff University. All
subjects provided written informed consent (or legal guardian consent and
subject assent).
The ICCBD includes BD cases and unaffected controls from the Sweden
Bipolar Disorder Cohort (SWEBIC), the Bipolar Disorder Research Network
(BDRN) in the United Kingdom, and the Genomic Psychiatry Consortium
(GPC) from the University of Southern California. Inter-rater reliability
across sites was performed and showed agreement between trained
clinicians on case status (Fleiss’ Kappa statistic for multiple raters κ= 0.72
for distinguishing BD from other disorders based on case notes; see
Supplementary Note). GWAS results have not been reported on 85.7% of
the ICCBD case subjects. All of the SWEBIC and BDRN control subjects have
been reported in prior GWAS of BD, schizophrenia and other disorders36,37
SWEBIC controls are from the Swedish Schizophrenia Consortium.36
SWEBIC cases were identified through four channels: two national
registries and two catchment areas. The Swedish National Quality
Assurance Registry for Bipolar Disorder (BipoläR) led to the ascertainment
of 1304 BD cases and the Swedish Hospital Discharge Register (HDR)
yielded 233 BD cases. The HDR case subjects have been previously
reported.38 Additional cases were obtained via two catchment areas: 271
cases were recruited via physician’s referral from the Affective Center at St.
Göran Hospital in Stockholm and 493 cases were recruited from the
greater Stockholm County region. SWEBIC controls were collected via the
HDR and have been reported elsewhere.36 All BD diagnoses for the SWEBIC
sample were made according to the DSM-IV criteria (Supplementary Note).
Genotype analyses have been previously reported for a portion of the
SWEBIC cases.38
Sample ascertainment strategies for the BDRN cases and controls have
been previously reported37,39 (Supplementary Note). BDRN controls are
from the Wellcome Trust Case Control Consortium 2 (WTCCC2) control
cohort.37 Case participants were interviewed using the Schedules for
Clinical Assessment in Neuropsychiatry (SCAN).40 Psychiatric and general
practice case-notes, where available, were also reviewed. On the basis of
these data best-estimate lifetime diagnoses were made according to DSM-
IV criteria and key clinical variables, such as age at onset and number of
episodes, were rated. In cases where there was doubt, diagnostic and
clinical ratings were made by at least two members of the research team
blind to each other’s rating. Team members involved in the interview,
rating and diagnostic procedures were all research psychologists or
psychiatrists. Green et al.39 reported 1218 BDRN cases for 3106 SNPs with
immunological annotations.
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GPC cases and controls were collected via the University of Southern
California healthcare system, as previously described.41 Using a combina-
tion of focused, direct interviews and data extraction from medical records,
diagnoses were established using the OPCRIT.42 Age and gender-matched
controls were ascertained from the University of Southern California health
system and assessed using a validated screening instrument and medical
records.
Genotyping
For all ICCBD sites, DNA was extracted from peripheral blood samples that
had been collected and stored at − 20 °C. Samples were then genotyped at
the Broad Institute. Genotypes were called using Birdsuite (Affymetrix,
Santa Clara, CA, USA) or BeadStudio (Illumina, San Diego, CA, USA).
Genotypes were generated as sufficient numbers of samples accumulated
from field work (Supplementary Note).
Quality control
Data were processed by a quality control (QC) pipeline modeled after the
central analysis pipeline of the PGCBD study.24 For each site, the goal was
to create a set of genotyped SNPs of high and uniform quality maximizing
the number of individuals retained. We first harmonized the SNP names,
position and strand, then removed duplicated SNPs and individuals. SNPs
with data missing in 45% of the sample were removed. Next, individuals
with heterozygosity rate 415%, missingness rate 42%, or whose
genotype-determined gender was ambiguous (0.25oFo0.75) were
removed. SNPs on sex chromosomes were removed from analysis, and
those remaining SNPs with data missing in 42% of the sample, minor
allele frequency (MAF)o1%, or deviation from Hardy–Weinberg equili-
brium (Po5 × 10− 5) were removed. For data sets containing both case
and control individuals, SNPs were also filtered based on differential
missingness in cases compared with controls (Po1× 10− 3) or differential
missingness based on haplotype (Po1× 10− 10). After these initial QC
checks, SNPs were pruned based on linkage disequilibrium (window
size = 100, window shift = 50 SNPs and VIF threshold= 2), and multi-
dimensional scaling (MDS) analysis on the N×N matrix of genome-wide
identity-by-state pairwise distances was performed. Outlier individuals
were identified using the ten most significant MDS components and
excluded from the analysis so that cases and controls were appropriately
matched. Relatedness between individuals in the population (defined as
PIHAT value40.1) was also evaluated, with one of the members being
removed from the analysis when such relationships were identified. After
all QC, there remained 6447 cases (1378 SWEBIC Illumina, 923 SWEBIC
Affymetrix, 2609 BDRN, 1537 GPC) and 12 639 controls (3716 SWEBIC
Illumina, 2215 SWEBIC Affymetrix, 5413 BDRN, 1295 GPC; Figure 1 and
Supplementary Note).
Phasing and imputation
After QC was completed on each of the ICCBD cohorts, phasing and
imputation was performed. The data were phased using SHAPEIT43 and
imputed using IMPUTE2,44 with phased 1000 Genomes world panel as
reference. Each data set was imputed separately, splitting the data sets
into 5MB imputation chunks. Following imputation, SNPs were filtered for
MAF40.01 and imputation quality score40.3. After applying these filters
to each cohort, meta-analysis was performed and only those SNPs with
high-quality data in all cohorts were retained for analysis. This resulted in
8 886 502 SNPs for the ICCBD GWAS and 8 837 380 SNPs for the ICCBD–
PGCBD meta-analysis.
Sign test
We performed sign tests on a modified ICCBD sample where duplicates or
related individuals between ICCBD and PGCBD had been removed (26
BDRN cases and 2610 BDRN controls). Sign tests were performed using
Figure 1. ICCBD sample description and analysis pipeline. The top panel (table) shows the composition of the ICCBD data set by site,
genotyping platform and phenotype. The three ICCBD sites are represented by color, and the BD subtypes by shade. The bottom panel uses
this representation of the dataset to diagram the workflow of the study and the portions of the ICCBD data set included in each analysis
presented in the manuscript. Thickened borders designate the included subset, while excluded subsets are colored in grey. The coloring of
text in the bottom panel is intended to illustrate how the same method (e.g., SNP-based heritability) was utilized for multiple purposes (i.e.,
ensuring similarity to previous GWAS, and comparing BD I to BD II). BD, bipolar disorder; GWAS, genome-wide association studies; ICCBD,
International Cohort Collection for Bipolar Disorder; SNP, single-nucleotide polymorphism.
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index SNPs from the PGCBD data in approximate linkage equilibrium with
association P-values below four thresholds (0.001, 1 × 10− 4, 1 × 10− 5 and
1× 10− 6).
Polygenic scoring
We carried out polygenic scoring analyses29 on the ICCBD data set using
the PGCBD discovery data set. Quantitative scores were computed for each
ICCBD subject based on the set of SNPs with P-values less than predefined
P-value thresholds (pT) in the discovery data set. For each SNP set defined
by pT, we calculated the proportion of variance explained (Nagelkerke's R2)
by subtracting the Nagelkerke's R2 attributable to ancestry covariates alone
from the Nagelkerke's R2 for polygenic scores plus covariates.
We additionally performed polygenic scoring analyses for three different
target BD subtypes within the ICCBD cohort: BD I; BD II; and SAB (Figures 1
and Supplementary Table 1). Polygene scores were calculated using three
discovery datasets: non-overlapping sets derived from GWAS of SCZ (9087
cases, 12 171 controls; cases included a small fraction of SAB),45 BD (6704
cases, 9381 controls; cases were 85% BD I, 11% BD II and 4% SAB)24 and
MDD (9041 cases, 9381 controls).46 The same set of controls was used in
each of the target sets, and targets sets were filtered such that there were
no overlaps with any of the discovery data sets. This yielded 3323 BD I
cases, 1340 BD II cases, 570 SAB cases and 7814 controls for analysis.
Quantitative scores were computed for each ICCBD subject at the defined
pT and for each SNP set we calculated the proportion of variance
explained (R2) by subtracting the Nagelkerke's R2 attributable to ancestry
covariates alone from the R2 for polygenic scores plus covariates. Next,
using the same three discovery data sets, we performed the same
polygene scoring procedure on target sets that, rather than containing
ICCBD cases and controls, contained two ICCBD subtype cohorts. Three
comparisons were performed in this manner: BD I vs BD II (3323 BD I cases,
1340 BD II cases), BD I vs SAB (3323 BD I cases, 570 SAB cases), and BD II vs
SAB (1340 BD II cases, 570 SAB cases).
Association analyses
All association analyses were conducted using logistic regression in
PLINK.32 MDS was performed on the entire data set, and each collection
wave was analyzed separately using as covariates those MDS components
in the top 10 that were significantly correlated with phenotype. Results
were then combined by meta-analysis in PLINK,32 and the heterogeneity P-
values reported are those for the Cochrane’s Q statistic. Association
analyses for BD were conducted using the 1000 Genomes imputed data.
We used a genome-wide significance threshold of Po5× 10− 8. Prior to
performing the ICCBD meta-analysis with the PGCBD, we reanalyzed the
PGCBD data set (7481 cases and 9250 controls)24 using 1000 Genomes
Project imputation, identifying no new genome-wide significant hits.
Heritability analyses
Using methods previously described,30–32 we estimated the variance in
liability explained by SNPs (SNP-h2) in the full ICCBD cohort and each
individual site for BD and its subtypes (Figure 1 and Supplementary Tables
1–3). From the set of 8 886 502 SNPs included in the ICCBD GWAS, we
further filtered to retain only SNPs that had imputation R2 of 40.8 and
MAF40.01 in all ICCBD samples, resulting in 7 252 417 SNPs upon which
to calculate genome-wide similarity relationships between all pairs of
individuals. For all SNP-h2 estimates reported, individuals were excluded to
ensure that no pairs of individuals had a genome-wide similarity
relationship 40.05. This procedure removes ancestry outliers in addition
to those already removed in the standard GWAS quality control pipeline.
To fully dissect whether previous observations of SNP-h2 heterogeneity
in BD30 were driven by subtype or site, further filtering was required to
ensure that the composition of the case cohorts being compared were
balanced in terms of these variables. Any subtype for which 475% of
cases derived from a single ICCBD site were thus excluded from these
analyses, limiting SNP-h2 subtype comparisons to BD I and BD II as 80% of
SAB cases were from GPC (Figure 1 and Supplementary Table 1). Next, any
site for which the relative contribution to the BD I and BD II case cohorts
9
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Figure 2. Association results for the ICCBD–PGCBD meta-analysis (13 902 cases, 19 279 controls). Horizontal axis shows chromosome and
position. Vertical axis shows the –log10 P-value for association with BD. The table shows detailed statistics of the index SNP from each
independent locus. The color of chromosome and SNP in the table corresponds the color of points for that locus in the Manhattan
plot. BD, bipolar disorder; ICCBD, International Cohort Collection for Bipolar Disorder; PGCBD, the Psychiatric Genomics Consortium Bipolar
Disorder Group; SNP, single-nucleotide polymorphism.
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was grossly imbalanced was excluded. This removed GPC from the SNP-h2
subtype analyses (Figure 1 and Supplementary Table 1).
Having applied these site/subtype filters, BD I and BD II SNP-h2 were
compared in the SWEBIC-BDRN cases using the full SWEBIC-BDRN control
set to calculate each subtype SNP-h2 (Supplementary Table 3). We then
applied a bivariate extension of these methods35 in order to estimate the
genetic correlation (rg) explained by SNPs between BD I and BD II cases (rg-
I/II), and to test whether it differed from rg between cohorts containing a
mix of BD I and BD II cases (rg-mix).
To avoid inflation of rg estimates, the SWEBIC-BDRN controls used in the
SNP-h2 calculations were randomly split into two evenly sized non-
overlapping groups, one each for pairing with the case subsets being
compared. We calculated 100 estimates of rg-I/II, each using the same BD I
(n=2811) and BD II (n= 1,398) case groups but a unique permutation of
the control splitting procedure. To calculate rg-mix, for each of the 100
control group permutations used in calculating rg-I/II we combined the BD I
and BD II cases into a single pool (n= 4,209 cases) that was then randomly
divided into two non-overlapping mixed case groups (that is, cohorts
containing both BD I and BD II cases) sized according to the BD I and BD II
case groups used in the rg-I/II estimates. We performed this case splitting
procedure 100 times for each of the 100 control group permutations,
for a total of 10 000 calculations of rg-mix. To determine whether the
distributions of rg-I/II and rg-mix estimates differed from one another, a t-test
was performed.
RESULTS
ICCBD GWAS and comparability to previous BD samples
Genome-wide SNP data of 6447 BD cases and 12 639 controls
matched for ancestry were analyzed from a previously unreported
population-based sampling in Sweden, the United Kingdom and the
United States (Supplementary Figure 1). We performed logistic
regression of case status on imputed dosages of 8 886 502
autosomal SNPs including sample and ancestry as covariates (see
Materials and Methods). The resulting genomic inflation factor (λ)47
was 1.11 (Figure 1 and Supplementary Figure 2). Two regions met a
genome-wide significance threshold of Po5×10−8: a 2 base-pair
deletion on chromosome 9 (position 129209201, risk allele = TC,
P=2.48×10−8, odds ratio (OR) =1.14), and a locus on chromosome
10 (position 111774807, rs10884920, risk allele =A, P=1.20×10−8,
OR= 1.17; Supplementary Table 4 and Supplementary Figure 3).
Neither variant has been previously reported to have an association
with BD, MDD, or SCZ. Comparability of this new cohort was
assessed in three ways. First, sign tests found that most ICCBD SNPs
had the same direction of effect as the index PGCBD SNP at
Po0.001 (66.73% in same direction, P=1.86×10−28; Supplemen-
tary Figure 4). Second, polygenic risk scoring found higher BD risk
scores in cases in the full ICCBD sample (P=5×10−89; Supplemen-
tary Figure 5). Third, we estimated the BD SNP-based heritability
(SNP-h2) using genome-wide complex trait analysis (GCTA)48 and
found a SNP-h2 of 0.24 (s.e. = 0.01; Supplementary Table 2),
consistent with previous estimates from the PGCBD sample.30
ICCBD–PGCBD meta-analysis
We combined the ICCBD cohort with PGCBD for a meta-analysis of
13 902 BD cases and 19 279 controls. Applying the same filters
used in the ICCBD GWAS yielded 8 032 748 SNPs for analysis.
There were 117 SNPs in 8 genomic regions that surpassed
genome-wide significance (Figure 2 and Supplementary Figure 3).
Of these, one region is novel; the chromosome 10 locus identified
in the ICCBD GWAS (chromosome 10, position 111774807,
rs10884920, P= 3.28 × 10− 8, heterogeneity P= 0.27, OR= 1.12).
Among the genes in strong linkage disequilibrium with this locus
Figure 3. SNP heritability and genetic correlation estimations for BD I and BD II. We estimated the SNP-h2 for BD I (n= 2,811 cases) and BD II
(n= 1398 cases), as well as the genetic correlation (rg) explained by SNPs between BD I and BD II (rg-I/II) and between random subsets of BD
cases (rg-mix). (a) Sample splitting procedures for SNP-based heritability and genetic correlation estimation. (b) SNP-based heritability estimates
for BD I and BD II. We observed a significant difference in the SNP-h2 of BD I and BD II (BD I SNP-h2= 0.35, SE= 0.02; BD II SNP-h2= 0.25,
SE= 0.04; two-sided t-test P= 0.02). (c) SNP-based heritability estimates for BD I and BD II stratified by cohort. (d) Genetic correlation estimates.
The distributions of the 100 rg-I/II and the 10 000 rg-mix estimates are presented. A significant difference between the distributions was
observed (P= 6.25 × 10−45 for a two-sided t-test of mean difference between the empirical rg-I/II and rg-mix distributions). BD, bipolar disorder;
BDRN, Bipolar Disorder Research Network; SNP, single-nucleotide polymorphism; SWEBIC, Swedish Bipolar Disorder Cohort.
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are adducin3 (ADD3), which codes for a ubiquitously expressed
cytoskeletal protein implicated in cerebral palsy,49 and amino-
peptidase P (XPNPEP1), which has been found to be involved in
the degradation and maturation of neuropeptides.50 Of the seven
other genome-wide significant signals, four were reported in the
PGCBD24 and an additional three by Chen et al.26 (Figure 2 and
Supplementary Table 5). When these eight loci were tested for
association with BD subtypes in the ICCBD cohort, the threshold for
nominal significance (Po0.05) was surpassed for all loci in BD I, four
loci in BD II and two loci in SAB (Supplementary Table 6). Moreover,
the direction of effect was the same as in the ICCBD–PGCBD for all
eight loci with respect to BD I and BD II, and for seven of the eight
loci with respect to SAB (Supplementary Table 6).
Heritability of BD I and BD II
We next compared BD subtypes with one another at the genetic
level by estimating SNP-based heritability (SNP-h2)[refs 30–32] with
GCTA.48 Traditional estimates of heritability infer the total genetic
contribution to the variance of a given phenotype through familial
relationships. In contrast, SNP-based estimation has the advantage
of harnessing actual genotype data, estimating the variance in
liability to disease that can be attributed to SNPs across the whole
genome. Reliable BD subtype SNP-h2 estimation required the
ICCBD sample analyzed be balanced with respect to disease
subtype and site of collection (see Materials and Methods). This
was found to be the case when considering BD I and BD II in the
SWEBIC and BDRN cohorts (2811 SWEBIC-BDRN BD I cases; 1398
SWEBIC-BDRN BD II cases; 11 164 SWEBIC-BDRN controls;
Supplementary Tables 1–3). We observed a significant difference
in the SNP-h2 of BD I and BD II (BD I SNP-h2 = 0.35, s.e. = 0.02; BD II
SNP-h2 = 0.25, s.e. = 0.04; two-sided t-test P-value = 0.02; Figure 3
and Supplementary Table 3).
We next estimated the genetic correlation between BD I and BD
II (rg-I/II)
[ref. 35] in SWEBIC–BDRN to directly assess their degree of
genetic overlap. In general, this method requires that each case
group be compared with an independent control group. In order
to compare the BD I cases (n= 2813) to the BD II (n= 1397) cases in
SWEBIC-BDRN, the 11 164 controls were therefore split into two
groups. We estimated rg-I/II to be 0.78, the mean of 100 estimates
calculated using 100 permutations of the splitting procedure used
to create independent control groups (range = 0.63–1.00, s.
d. = 0.07; see Materials and Methods; Figure 3). Positive rg values
are observed when case groups share the same risk alleles relative
to controls. In principle, this value should equal one when the two
case groups are random samples of the same case population.
Indeed, when genetic correlations were estimated between case
groups containing random mixtures of BD subtypes (rg-mix; see
Materials and Methods), a mean value of 0.97 was observed
(range = 0.64–1.00, s.d. = 0.05). The distribution of rg-mix estimates
was significantly higher than the distribution of rg-I/II estimates,
suggesting the genetic heterogeneity observed between BD I and
BD II is non-random and not simply a function of BD being a
complex genetic disease (P= 6.25 × 10− 45 for t-test of mean
difference between the empirical rg-I/II and rg-mix distributions;
Figure 3).
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Polygenic scoring of BD subtypes
Figure 4. Comparison of BD subtypes with one another and controls using bipolar disorder (BD), schizophrenia (SCZ) and major depressive
disorder (MDD) polygenic scores. Regression analyses of phenotype (top: BD subtype vs controls; bottom: BD subtype vs BD subtype) on
polygenic scores derived from three previous GWAS (blue—BD, red—SCZ and green—MDD) were performed using MDS components and
study site as covariates. The t-statistic plotted on the x axis is the ratio of the coefficient of the polygenic score variable and its standard error
from the generalized linear model regression equation. The direction of the plotted bars indicates the phenotype in the comparison with the
higher polygenic scores. The P-values for whether scores differed significantly between phenotypes are shown at the far right. Nagelkerke’s R2
values were derived from a corresponding logistic regression analysis performed for each phenotype comparison, and are used as to estimate
the variance in phenotype explained by the polygenic score. GWAS, genome-wide association studies.
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Polygenic scoring of BD subtypes
Polygenic scoring29 was also used to assess the relationships
between disease subtypes (see Materials and Methods). Risk
scores were derived for each individual in the data set by counting
the number of alleles present that have previously shown to
increase disease risk across a range of P-value thresholds. Logistic
regression was performed between diagnosis and risk score with
site and the first 10 MDS components as covariates to test for
significant correlation between BD subtype and SCZ, MDD, and BD
genetic risk. For all subtypes tested, each discovery set produced a
significantly higher polygenic risk score for cases compared with
controls, with the most significant correlation being that between
BD risk scores and diagnosis of BD I (P= 2.75 × 10− 62, pseudo-
R2 = 0.033; Figure 4). MDD risk scores were the least significant
across all subtypes (BD I P= 8.92 × 10− 7, BD II P= 4.34 × 10− 7, SAB
P= 0.002). Next, we examined the ability of these risk scores to
differentiate subtypes from each other. We again performed
logistic regression on risk score except comparing BD subtypes to
one another rather than to controls. BD risk scores had significant
discriminant ability when comparing BD I and BD II, with more BD
risk alleles found in BD I (P= 5.45 × 10− 7). In addition, we identified
significantly more SCZ risk alleles in BD I compared to BD II
(P= 0.001), SAB compared with BD I (P= 3.86 × 10− 4), and SAB
compared with BD II (P= 1.41 × 10− 4; Figure 4). MDD risk scores
did not show significant discriminant ability between any pair of
BD subtypes, though were higher in BD II compared to BD I
(P= 0.06) and in BD I compared with SAB (P= 0.88; Figure 4).
DISCUSSION
We present a BD GWAS with over 5000 previously unreported
cases (totaling 13 902 cases and 19 279 controls) identifying eight
genome-wide significant loci, including a novel locus on chromo-
some 10. The new locus contains two coding genes, adducin 3
(ADD3) and aminopeptidase P (XPNPEP1) and a non-coding RNA
also annotated as an antisense ADD3 RNA. Both genes are
biologically interesting in relation to BD. First, ADD3 is a member
of a family of cytoskeletal proteins responsible for capping the
growing end of actin filaments and promoting the binding of
spectrin to actin in the brain and elsewhere. Recently, adducins
have been shown to form ladder-like structures in axons similar to
those observed for actin and spectrin.51 Previously, genetic
alterations in other components of the actin cytoskeleton have
been suggested as risk factors for both BD and SCZ.52 Second,
XPNPEP1 is an X-prolyl aminopeptidase that mediates the
proteolytic cleavage of the N-terminal amino acid in peptides
with proline. Proline containing neuropeptides include oxytocin,
corticotropin releasing hormone, neuropeptide Y and substance
P,53 each of which has been implicated with varying levels of
support in BD. Heterozygous mice in which XPNPEP1 was deleted
had smaller forebrains also consistent with a potential role in
neuropsychiatric illness.54
Of the 12 loci previously reported genome-wide significant in at
least 1 of the 3 largest BD GWAS, 9 have P-values below 10− 6 in
our data set and 7 of these surpass genome-wide significance
(Supplementary Table 5). One straightforward explanation for our
ability to support some, but not all prior BD loci, is the possibility
of ‘winner’s curse’.55 Given a polygenic model, the power will be
low to detect a particular variant (due to the overestimation of the
power to replicate individual results) at genome-wide significant
threshold, though there will be many chance opportunities to
identify at least one variant.55 Thus any single lack of replication is
not informative. In general, however, our data strongly support
consistency of our samples with the prior literature as reflected by
the sign test with the prior PGCBD samples (Supplementary
Figure 4), significant polygenic risk prediction (Supplementary
Figure 5) and BD heritability estimates (Supplementary Table 2)
consistent with previous estimates.30
In this paper, we provide evidence of a molecular correlate for
the division of BD into types I and II. SNP-h2 was observed to be
significantly higher in BD I compared with BD II. This observation
led us to test the null hypothesis that BD I and BD II are the same
genetic trait (that is, rg, I/II = rg, mix). The mean rg, I/II and rg, mix
values were significantly different from one another, supporting
the notion that BD I and BD II cohorts have a significantly lower
genetic correlation than two BD cohorts composed of both
subtypes. In addition to SNP-h2 and rg analyses, we found that
polygenic score profiles of BD and SCZ risk variants had significant
discriminant ability between BD I and BD II. The BD risk variants
used for scoring were originally discovered in a cohort that is 85%
BD I and 11% BD II,24 thus the lower scores in the ICCBD BD II
cohort is consistent with BD II having partially distinct risk loci. The
discriminant ability of SCZ risk variants with higher scores in BD I is
consistent with clinical phenomenology, as psychosis is far more
commonly a feature of BD I than BD II.56 We hypothesized that
MDD risk scores would be significantly higher in BD II compared
with BD I due to the prominent depressive episodes required for a
diagnosis of BD II. This was not found to be the case, though a
non-significant trend in the predicted direction was observed.
The number of SAB cases in the ICCBD cohort allowed us to
begin to assess its genetic overlap with BD I and BD II. Subtype-
specific association results for the eight loci identified as
significant in the ICCBD–PGCBD GWAS showed the expected
direction of effect for all three subtypes at seven loci and for two
of the three subtypes (BD I and BD II) at one locus (Supplementary
Table 6). Thus, for these eight most significant loci, the association
does not appear to be driven by a particular subtype of disease.
Clinically, SAB is unique among BD subtypes in that psychosis in
the absence of mania and depression is required for a diagnosis.
As such, one may expect that the psychosis risk loci from studies
of SCZ would demonstrate discriminant ability between SAB and
other BD subtypes, which is indeed what we observe. We see a
pattern of SCZ risk loci loading that follows the prominence of
psychotic symptoms in the phenomenology of the three BD
subtypes (SAB4BD I4BD II). One interpretation of these findings
is that the genetic liability of psychosis influences the prominence
of psychotic symptoms across diagnostic entities, ranging from
psychosis being the sole feature and occurring only in the absence
of mania or depression (that is, SCZ), to being a feature occurring
in both the presence and absence of mania or depression (that is,
SA), to being a common but not required feature occurring only in
the presence of mania or depression (that is, BD I), to finally being
a feature occurring rarely and only in the presence of depression
(that is, BD II and MDD). However, it should be noted that the SCZ
risk variants used for scoring were discovered in a dataset
(PGCSCZ45) that included SA cases. Of the 5 PGCSCZ cohorts that
included SA, three explicitly reported the percentage of SA cases,
which ranged from 6 to 17% of the total cohort sample (the
percent of these cases with SAB is unavailable).45 Therefore, the
increased SCZ loading in SAB observed here could in part reflect
genetic signal from SAB cases in the PGCSCZ discovery set in
addition to (or, as opposed to) reflecting an increased loading for
risk variants specific to psychosis. In order to further address these
possibilities through genetics, larger SAB cohorts such as those
that will be available in larger consortia are necessary.
This study has several limitations. Although our sample sizes for
BD subtype comparisons are larger than those previously
reported, we were still relatively underpowered to perform
subtype-specific GWAS. As is common for most large-scale genetic
studies in psychiatry, we were not able to assess higher-
dimensional phenotypes (that is, age of onset, lithium response)
since this information is not currently available for all ICCBD
subjects. Finally, heterogeneity between sites was observed in our
analyses, most notably in that the GPC cohort demonstrated
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relatively decreased signal compared with the SWEBIC and BDRN
cohorts. Such heterogeneity is not uncommon in genetic studies
that pool samples from many different sites, but also raises the
possibility that technical artifacts or subtle confounders (that is,
cryptic relatedness) unable to be detected using current methods
may be blunting the signal. When possible, the potential for such
batch effects was taken into account (Supplementary Note).
In summary, in addition to providing a new and interesting
locus for BD, our findings begin the process of correlating
molecular signatures with disorders on the bipolar spectrum of
mental illness. Increasingly, it is realized that there is genetic
overlap between psychiatric diagnoses. Here we add nuance to
our understanding of this phenomenon, providing evidence that
genetic overlap correlates with overlap in clinical phenomenology.
Ultimately, these analyses could lead to refined distinctions with
the potential to improve prognosis and treatment strategies.
Whether there are other dimensional measures that may better
reflect the underlying genetic architecture remains to be tested in
larger consortia samples as increasingly refined phenotyping is
available.
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